Jeong A Kim | Medicine and Dentistry | Best Researcher Award

Published on 25/02/202525/02/2025 by Book of Award

Prof. Jeong A Kim | Medicine and Dentistry | Best Researcher Award

St. Vincent Hospital, The Catholic University of Korea | South Korea

Author Profile

Early Academic Pursuits ✨

Prof. Jeong A Kim embarked on an illustrious academic journey in the field of medicine, laying a solid foundation at the Catholic University Medical College. She completed her premedical course in 1986, followed by earning her Doctor of Medicine degree in 1990. Her passion for internal medicine and hematology led her to pursue advanced studies at The Catholic University of Korea, where she obtained a Master’s degree in 1998 and a Ph.D. in 2001. This strong academic background established her as a dedicated scholar committed to the advancement of medical sciences.

Professional Endeavors 🏥

Prof. Kim's professional career began with rigorous postdoctoral training. She completed her internship at St. Mary’s Hospital in 1991, followed by a residency in Internal Medicine at Catholic University Medical College until 1995. She further honed her expertise in hemato-oncology through a fellowship at Samsung Medical Center. Her international exposure expanded when she joined the Department of Microbiology and Immunology at IUPUI, USA, as a postdoctoral researcher. Her academic appointments at The Catholic University of Korea saw a steady rise, from Instructor in 1997 to Assistant Professor in 2001, Associate Professor in 2009, and finally attaining the prestigious title of Professor of Internal Medicine in 2014. In parallel, she has been a dedicated physician at St. Vincent Hospital since 1997 and has been leading the hematology and stem cell transplantation center since 2018.

Contributions and Research Focus 📝

Prof. Kim has made groundbreaking contributions in hematology and oncology, with a primary focus on stem cell transplantation, multiple myeloma, and lymphoma. Her extensive clinical trials and research studies have played a pivotal role in developing new treatment modalities for hematologic malignancies. Her work in targeted therapies, chemotherapy combinations, and immunotherapy has significantly improved patient outcomes and quality of life. She has been involved in more than 60 clinical trials, evaluating novel drug efficacy and safety, including studies on Zoledronic acid for multiple myeloma, targeted treatments like Dasatinib for leukemia, and the role of rituximab in lymphoma. Her research has also delved into prognostic factors, precision medicine, and innovative therapeutic strategies for refractory and relapsed hematologic diseases.

Accolades and Recognition 🏆

Prof. Kim's relentless pursuit of excellence has earned her recognition from esteemed medical institutions and societies. As a member of the Korean Association of Internal Medicine, the Korean Hematology Association, and the American Hematology Association, she has played an instrumental role in shaping global hematologic research. Her contributions have been acknowledged through numerous awards, invitations as a keynote speaker, and influential publications in high-impact medical journals.

Impact and Influence ✨

With a career spanning decades, Prof. Kim has mentored numerous young medical professionals, guiding them in clinical research and evidence-based medical practice. Her work has directly influenced hematologic treatment protocols in Korea and internationally. Her leadership in hematology and stem cell transplantation has set new benchmarks in patient care and innovative treatment approaches.

Legacy and Future Contributions 🌟

Prof. Jeong A Kim's legacy is deeply ingrained in the advancements of hematology and oncology. Her dedication to research, patient care, and education continues to inspire the next generation of medical professionals. Looking ahead, she remains committed to pioneering more targeted therapies, enhancing stem cell transplantation techniques, and improving long-term survival rates for hematologic malignancy patients. With ongoing research and collaborations, she is poised to make even greater strides in the field, leaving an indelible mark on medical science and patient care.

Publications

📄 The presence of clonal isotype switch after autologous stem cell transplantation as a prognostic biomarker for long-term survival in patients with multiple myeloma
Authors: H. Cho, J. Kim, Y. Park, Y. Kim, J. Kim, Jeong-ah
Journal: Leukemia Research
Year: 2025

📄 Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
Authors: N.L. Bartlett, U.H. Hahn, W. Kim, F. Jie, J. Kim, Jeong-ah
Journal: Journal of Clinical Oncology
Year: 2025

📄 Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trials
Authors: D. Shin, S. Park, E. Jang, W. Lee, D. Kim
Journal: Leukemia Research
Year: 2024

📄 Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study
Authors: H.Y. Yhim, Y. Park, J. Kim, Jeong-ah, D. Yang, J. Kwak
Journal: The Korean Journal of Internal Medicine
Year: 2024

Panupong Hansrivijit | Health Professions | Best Researcher Award

Published on 12/02/202512/02/2025 by Book of Award

Dr. Panupong Hansrivijit | Health Professions | Best Researcher Award

Brigham and Women's Hospital | United States

Author Profile

Scopus

Orcid

Google Scholar

🌟 Early Academic Pursuits

Dr. Panupong Hansrivijit embarked on his medical journey at Chulalongkorn University, where he graduated with first-class honors in medicine. His passion for internal medicine and nephrology led him to pursue an internship at Thammasat University Hospital, where he gained extensive clinical experience in patient care and medical procedures. This strong academic foundation set the stage for his future endeavors in nephrology research and clinical excellence.

🏥 Professional Endeavors

Dr. Hansrivijit’s medical career took him to the United States, where he completed his Internal Medicine Residency at UPMC Harrisburg. This period was crucial in shaping his skills in patient diagnosis, management, and research methodologies. Currently, he is a Nephrology Fellow at Brigham and Women’s Hospital/Massachusetts General Hospital, specializing in managing complex kidney disorders, dialysis, and transplantation. Simultaneously, he is advancing his expertise in public health through a Master of Public Health (MPH) at Harvard T.H. Chan School of Public Health.

🔬 Contributions and Research Focus

Dr. Hansrivijit has made significant contributions to the field of nephrology, particularly in chronic kidney disease, dialysis, kidney transplantation, and pharmaco-epidemiology. His research spans multiple areas, including machine learning applications in kidney disease prediction, outcomes of kidney transplant recipients, and the impact of metabolic disorders on renal health. His extensive list of publications reflects his dedication to evidence-based medicine and improving patient outcomes.

🏆 Accolades and Recognition

Dr. Hansrivijit's groundbreaking work has earned him multiple prestigious awards, including the Best Researcher Award (2025) from both the International Environmental Awards and the International Invention Awards. His achievements also include multiple Kidney STARS Program Awards from the American Society of Nephrology, a Travel Grant Award from the International Society of Nephrology, and recognition for his contributions to global nephrology research.

🌍 Impact and Influence

Beyond his clinical and research work, Dr. Hansrivijit is an active member of the nephrology community, holding memberships in renowned organizations such as the National Kidney Foundation (NKF) and the American Society of Nephrology (ASN). His contributions in meta-analyses, systematic reviews, and nephrology-based epidemiological research have influenced treatment strategies and policy discussions on kidney disease management worldwide.

🚀 Legacy and Future Contributions

With a growing portfolio of influential research and clinical expertise, Dr. Hansrivijit is set to become a leader in nephrology innovation. His future contributions will likely focus on improving dialysis techniques, optimizing transplant outcomes, and utilizing data-driven methodologies to enhance patient care. His dedication to advancing kidney health and public health policies ensures that his impact will be felt for generations to come.

Publications

📄 Utilization Trends of Glucose-Lowering Medications Among Adult Kidney Transplant Recipients with Type 2 Diabetes in the United States
Author(s): Panupong Hansrivijit, Helen Tesfaye, Deborah J. Wexler, Elisabetta Patorno, Julie M. Paik
Journal: Journal of Clinical Medicine
Year: 2025

📄 A Hospice Transitions Program for Patients in the Emergency Department
Author(s): Christopher William A. Baugh, Kei Ouchi, Jason K. Bowman, Elizabeth M. Rickerson, Mallika Lakshmi Mendu
Journal: JAMA Network Open
Year: 2024

📄 Unpacking Contributors to CKD Incidence and Progression: Time to Move Beyond Traditional Risk Factors
Author(s): Panupong Hansrivijit, Lipika Samal, Mallika Lakshmi Mendu
Journal: American Journal of Kidney Diseases
Year: 2023

📄 Hepatitis E Virus Infection in Hematopoietic Stem Cell Transplant Recipients: A Systematic Review and Meta-Analysis
Author(s): Angkawipa Trongtorsak, Natapat Chaisidhivej, Kritika Yadav, Wisit Cheungpasitporn, Panupong Hansrivijit
Journal: Journal of Investigative Medicine
Year: 2022

📄 Renal Manifestations of Hepatitis E Among Immunocompetent and Solid Organ Transplant Recipients
Author(s): Karthik Reddy Kovvuru, Nicholas Carbajal, Abhinandan Reddy Pakanati, Wisit Cheungpasitporn, Swetha Rani Kanduri
Journal: World Journal of Hepatology
Year: 2022

Shadi Hamoud | Medicine and Dentistry | Best Researcher Award

Published on 18/10/202418/10/2024 by Book of Award

Assist Prof Dr. Shadi Hamoud | Medicine and Dentistry | Best Researcher Award

Rambam Health Care Campus | Israel

Author Profile

Orcid

Early Academic Pursuits 🎓

Dr. Shadi Hamoud's academic journey began with the completion of his MD (cum laude) from the Faculty of Medicine at the Hebrew University, Jerusalem, in 1995. His commitment to medical excellence was evident from the beginning, as he specialized in Internal Medicine during his residency at Rambam Medical Center from 1996 to 2002. His passion for teaching also emerged early, as he served as a tutor and lecturer for medical students and advanced nursing courses at Rambam Health Care Campus.

Professional Endeavors 🏥

Dr. Hamoud has held several key roles throughout his career. Since 2010, he has been the Director of the Clinical Research Unit at the Internal Medicine E Department, Rambam Medical Center. He also serves as the Deputy Director of the same department. His expertise is sought by major pharmaceutical companies such as Bayer and Pfizer, where he has been a medical consultant since 2016 and 2017, respectively. Additionally, Dr. Hamoud plays a vital role on various medical committees, including the committee for blood product transfusions at Rambam and the specialty committee within the hospital.

Contributions and Research Focus 🔬

Dr. Hamoud's research interests are broad, focusing on critical issues in cardiovascular medicine, diabetes, and novel COVID-19 treatments. He has investigated lipoprotein oxidation and atherosclerosis, as well as the enzyme heparanase and its impact on kidney injuries, fatty liver disease, and other conditions. His involvement in international clinical trials and research on lipid-modifying drugs and new oral anticoagulants highlights his commitment to advancing medical science.

Accolades and Recognition 🏅

Dr. Hamoud has received numerous awards throughout his career, recognizing his dedication to both medicine and education. Between 2003 and 2016, he was named an Excellent Lecturer by the Internal Medicine E Department at Rambam Health Care Campus. In 2008, he was also honored with an Excellence in Medicine award, further cementing his reputation as a distinguished medical professional.

Impact and Influence 🌍

Dr. Hamoud’s influence extends beyond academia and clinical practice. He has been actively involved in public health education, delivering lectures at local schools in his hometown of Majd Al-Kurum. His role as an examiner in Israel’s internal medicine specialization exams underscores his commitment to shaping the next generation of medical professionals. He has also contributed to the medical field through his membership in professional societies, including the European Society of Hypertension and the Israeli Society of Hypertension.

Legacy and Future Contributions 🌱

Dr. Hamoud's work in medical research, clinical practice, and education has left a lasting impact on the healthcare field in Israel and beyond. His ongoing roles in clinical research, his contributions to new therapies for chronic diseases, and his mentorship of future doctors ensure that his influence will continue to grow. As a leader in both medicine and research, his legacy is one of commitment to improving health outcomes and advancing scientific knowledge for the benefit of future generations

Publications

📄"Gender-Specific Renoprotective Pathways in αMUPA Transgenic Mice Subjected to Acute Kidney Injury" 🐭
Authors: Heba Abd Alkhaleq, Shadi Hamoud, Israel Hacker, Tony Karram, Ahmad Fokra, Aviva Kabala, Zaid Abassi
Journal: International Journal of Molecular Sciences
Year: 2024

📄"Effects of Angiotensin 1-7 and Mas Receptor Agonist on Renal System in a Rat Model of Heart Failure" 🐀
Authors: Ravit Cohen-Segev, Omri Nativ, Safa Kinaneh, Doron Aronson, Aviva Kabala, Shadi Hamoud, Tony Karram, Zaid Abassi
Journal: International Journal of Molecular Sciences
Year: 2023

📄"Heparanase Inhibition Prevents Liver Steatosis in E₀ Mice" 🧬
Authors: Safa Kinaneh, Walaa Hijaze, Lana Mansour-Wattad, Rawan Hammoud, Hisam Zaidani, Aviva Kabala, Shadi Hamoud
Journal: Journal of Clinical Medicine
Year: 2022

Feifei Feng | Health Professions | Best Researcher Award

Published on 10/07/202411/07/2024 by Book of Award

Dr. Feifei Feng | Health Professions | Best Researcher Award

The Second Hospital of Shandong University | China

Author Profile

Scopus

Early Academic Pursuits

Dr. Feifei Feng embarked on her academic journey in clinical medicine, obtaining a Master's degree through a seven-year program at Zhejiang University (2005-2012). She continued her education with a Doctor of Medicine (MD) degree in Internal Medicine from Qilu Medical College, Shandong University (2017-2020). Her academic training laid a robust foundation in both clinical and research aspects of internal medicine, particularly focusing on respiratory and critical care.

Professional Endeavors

Dr. Feng's professional career has been marked by her role as an Associate Chief Physician in the Department of Respiratory and Critical Care Medicine at the Second Hospital of Shandong University (09/2022 - Present). In this capacity, she is responsible for the daily consultation and treatment of patients with respiratory and critical care needs. Her work emphasizes the diagnosis and management of respiratory diseases, with a particular focus on lung cancer and pulmonary fibrosis.

Contributions and Research Focus

Dr. Feng's research has significantly contributed to understanding and treating respiratory diseases. Her research focus includes:

*Silicosis and Pulmonary Fibrosis: Dr. Feng has extensively studied the pathogenesis of silicosis and the therapeutic effects of compounds like Tanshinone IIA in attenuating silica-induced pulmonary fibrosis.

*Cancer Therapy: Her work on the inhibitory effects of polyphyllins and their role in enhancing chemosensitivity of cancer cells to treatments like cisplatin has been groundbreaking.

*Signaling Pathways: She has delved into the molecular mechanisms underlying disease processes, such as the TGF-β1/Smad signaling pathway, EMT, NOX4 inhibition, and Nrf2/ARE signaling activation.

Accolades and Recognition

Dr. Feng's contributions to the field have been widely recognized through numerous publications in high-impact journals. Some of her notable works include:

"Role of TRIM59 in regulating PPM1A in the pathogenesis of silicosis and the intervention effect of tanshinone IIA" (Biomed Pharmacother, 2024).

"Tanshinone IIA attenuates silica-induced pulmonary fibrosis via Nrf2-mediated inhibition of EMT and TGF-β1/Smad signaling" (Chem Biol Interact, 2020).

Impact and Influence

Dr. Feng's research has had a profound impact on the medical community's understanding of respiratory diseases and their treatment. Her studies on the molecular pathways involved in pulmonary fibrosis and cancer therapy have opened new avenues for developing targeted treatments. By elucidating the mechanisms of disease and identifying potential therapeutic agents, her work has contributed to improved patient outcomes and advanced the field of respiratory medicine.

Legacy and Future Contributions

Dr. Feng continues to make strides in her field through her ongoing clinical practice and research. Her dedication to understanding complex respiratory diseases and finding innovative treatments ensures that her contributions will have a lasting impact. Future research endeavors are likely to build on her current work, exploring new therapeutic targets and improving the quality of care for patients with respiratory diseases. Her legacy will be marked by her commitment to advancing medical science and improving patient health outcomes.

Notable Publications

Role of TRIM59 in regulating PPM1A in the pathogenesis of silicosis and the intervention effect of tanshinone IIA 2024

Polyphyllin I induces apoptosis and autophagy in temozolomide-resistant glioma via modulation of NRF2 and MAPK-signaling activation 2023 (2)

Ginsenoside Rb1 Alleviates Bleomycin-Induced Pulmonary Inflammation and Fibrosis by Suppressing Central Nucleotide-Binding Oligomerization-, Leucine-Rich Repeat-, and Pyrin Domains-Containing Protein Three Inflammasome Activation and the NF-κB Pathway 2022 (8)

Detection and significance of exosomal mRNA expression profiles in the cerebrospinal fluid of patients with meningeal carcinomatosis 2021 (6)

Astragaloside IV alleviates silica‑induced pulmonary fibrosis via inactivation of the TGF‑β1/Smad2/3 signaling pathway 2021 (23)